<article id="aarts_2010" class="slide" data-ag-slide-name="Aarts 2010">
    <div class="basic">
      <h1 data-ag-editable="Aarts 2010 Main Title">If Neulasta<sup>速</sup> is used in all cycles, the vast majority of your patients can avoid FN<sup>1</sup></h1>
      <div id="ne_page2_data_top"><p data-ag-editable="Aarts 2010 Top Copy">Patients at risk of FN require Neulasta<sup>速</sup> throughout all cycles<sup>1</sup></p></div>
      <div id="ne_page2_section1_holder" class="main_content_style">
         <h2 data-ag-editable="Aarts 2010 Content 1 Header">1 in 4 Patients</h2>
         <p data-ag-editable="Aarts 2010 Content 1 Copy">experienced FN when Neulasta<sup>速</sup> was used only<br/> in the first two cycles<sup>1</sup></p>
         <div id="ne_page2_section1_inner">
            <div id="ne_page2_section1_image"></div>
         </div>
      </div>
      <div id="ne_page2_section1_hide"></div>
      <div id="ne_page2_section2_holder" class="main_content_style">
         <div id="ne_page2_section2_copy_holder">
            <p data-ag-editable="Aarts 2010 Content 2 Copy">When Neulasta<sup>速</sup> was<br/> used in all cycles,<br/> this risk dropped to</p>
            <h2 data-ag-editable="Aarts 2010 Content 2 Header">1 in 26 Patients<sup>1</sup></h2>
         </div>
         <div id="ne_page2_section2_inner">
            <div id="ne_page2_section2_image_pt1"></div>
            <div id="ne_page2_section2_image_pt2"></div>
         </div>
      </div>
      <div id="ne_page2_section2_hide"></div>
      <div id="ne_page2_data_bottom" data-ag-editable="Aarts 2010 Bottom Copy">The study was stopped after a planned interim analysis based on the differences in the incidence of FN</div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="aarts_2010_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Aarts 2010 References Title">References:</strong></p>
          <div data-ag-editable="Aarts 2010 References List">
             <ol>
                <li>Aarts M <em>et al</em>. Primary G-Csf Prophylaxis During The First Two Cycles Only Or Throughout All Chemotherapy Cycles In Breast Cancer Patients At Risk Of Febrile Neutropenia: First Results From A Phase III Trial Of The Dutch Breast Cancer Trialists Group (Boog). Supp Care Cancer 2010; 18(Suppl 3):S115-116</li>
             </ol>
          </div>
          <p data-ag-editable="Aarts 2010 References Bottom Copy">Breast cancer patients (n=162) with an increased risk of FN (&gt;20%) were randomized 1:1 to primary G-CSF prophylaxis during the first two chemotherapy cycles only, or to prophylaxis throughout all cycles.</p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>